keyword
MENU ▼
Read by QxMD icon Read
search

gastro plus

keyword
https://www.readbyqxmd.com/read/28376151/local-treatment-of-unresectable-colorectal-liver-metastases-results-of-a-randomized-phase-ii-trial
#1
Theo Ruers, Frits Van Coevorden, Cornelis J A Punt, Jean-Pierre E N Pierie, Inne Borel-Rinkes, Jonathan A Ledermann, Graeme Poston, Wolf Bechstein, Marie-Ange Lentz, Murielle Mauer, Gunnar Folprecht, Eric Van Cutsem, Michel Ducreux, Bernard Nordlinger
Background: Tumor ablation is often employed for unresectable colorectal liver metastases. However, no survival benefit has ever been demonstrated in prospective randomized studies. Here, we investigate the long-term benefits of such an aggressive approach. Methods: In this randomized phase II trial, 119 patients with unresectable colorectal liver metastases (n < 10 and no extrahepatic disease) received systemic treatment alone or systemic treatment plus aggressive local treatment by radiofrequency ablation ± resection...
September 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28343975/trastuzumab-emtansine-versus-taxane-use-for-previously-treated-her2-positive-locally-advanced-or-metastatic-gastric-or-gastro-oesophageal-junction-adenocarcinoma-gatsby-an-international-randomised-open-label-adaptive-phase-2-3-study
#2
Peter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A Ajani, Hugo Castro, Wasat Mansoor, Hyun Cheol Chung, Gyorgy Bodoky, Kohei Shitara, Gail D Lewis Phillips, Tina van der Horst, Marie-Laurence Harle-Yge, Betsy L Althaus, Yoon-Koo Kang
BACKGROUND: Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is no established therapy in the second-line setting. In GATSBY, we examined the efficacy and tolerability of trastuzumab emtansine in patients previously treated for HER2-positive advanced gastric cancer (unresectable, locally advanced, or metastatic gastric cancer, including adenocarcinoma of the gastro-oesophageal junction). METHODS: This is the final analysis from GATSBY, a randomised, open-label, adaptive, phase 2/3 study, done at 107 centres (28 countries worldwide)...
March 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28155594/pbpk-modeling-a-predictive-eco-friendly-bio-waiver-tool-for-drug-research
#3
Baishakhi De, Koushik Bhandari, Ranjan Mukherjee, Prakash Katakam, Shanta K Adiki, Rohit Gundamaraju, Analava Mitra
BACKGROUND: The world has witnessed growing complexities in disease scenario influenced by the drastic changes in host-pathogen- environment triadic relation. Pharmaceutical R&Ds are in constant search of novel therapeutic entities to hasten transition of drug molecules from lab bench to patient bedside. Extensive animal studies and human pharmacokinetics are still the "gold standard" in investigational new drug research and bio-equivalency studies. Apart from cost, time and ethical issues on animal experimentation, burning questions arise relating to ecological disturbances, environmental hazards and biodiversity issues...
February 1, 2017: Current Drug Discovery Technologies
https://www.readbyqxmd.com/read/28133089/-strategy-for-unresectable-pancreatic-cancer-with-stenosis-of-the-duodenum-a-case-report
#4
Masahiko Komagome, Riki Ninomiya, Akiko Nakazawa, Tetsuya Mitsui, Akira Maki, Fumiaki Ozawa, Yoshifumi Beck
Unresectable(UR)pancreatic cancer often causes duodenal obstruction. Case 1: A 58-year-old man was diagnosed with UR pancreatic cancer with obstruction of the 3rd duodenal portion. A duodenum 2nd portion jejunum bypass was performed, and FOLFIRINOX was introduced and continued over 6 months. Case 2: A 74-year-old man was diagnosed with UR pancreatic cancer with obstruction of the duodenum near the Treitz ligament. A duodenum 3rd portion jejunum bypass was performed, and gemcitabine plus nab-paclitaxel was introduced...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28072691/the-effectiveness-and-safety-of-dual-antiplatelet-therapy-in-ischemic-cerebrovascular-disease-with-intracranial-and-extracranial-arteriostenosis-in-chinese-patients-a-randomized-and-controlled-trail
#5
RANDOMIZED CONTROLLED TRIAL
Feng-Tong Zuo, Hui Liu, Hui-Jun Wu, Na Su, Jie-Qiong Liu, Ai-Qin Dong
BACKGROUND: There are limited data on the effect of dual antiplatelet treatment with clopidogrel plus aspirin in patients with ischemic cerebrovascular disease and intracranial and extracranial arteriostenosis. The aim of our study was to evaluate the efficacy and safety of aspirin plus clopidogrel in the treatment of ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis. METHODS: Patients with clinically evident acute cerebral infarction or transient ischemic attack combined with intracranial and extracranial arteriostenosis (greater than 50%) who were unsuitable or reluctance to perform stent implantation were enrolled in this study...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28070826/interaction-of-ethnicity-and-h-pylori-infection-in-the-occurrence-of-microscopic-colitis
#6
Amnon Sonnenberg, Kevin O Turner, Robert M Genta
BACKGROUND: Previous studies found that microscopic colitis is inversely associated with Helicobacter pylori infection and that microscopic colitis is characterized by a marked ethnic variation. AIM: The aim of the present study was to test whether an underlying ethnic variation of H. pylori infection is responsible for the ethnic variation of microscopic colitis. METHODS: The Miraca Life Sciences Database is a large national electronic repository of histopathologic records of patients distributed throughout the entire USA...
April 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/27973989/prospective-randomized-controlled-study-on-the-effects-of-saccharomyces-boulardii-cncm-i-745-and-amoxicillin-clavulanate-or-the-combination-on-the-gut-microbiota-of-healthy-volunteers
#7
Toufic A Kabbani, Kumar Pallav, Scot E Dowd, Javier Villafuerte-Galvez, Rohini R Vanga, Natalia E Castillo, Joshua Hansen, Melinda Dennis, Daniel A Leffler, Ciarán P Kelly
Probiotics are believed to be beneficial in maintaining a healthy gut microbiota whereas antibiotics are known to induce dysbiosis. This study aimed to examine the effects of the probiotic Saccharomyces boulardii CNCM I-745 (SB), the antibiotic Amoxicillin-Clavulanate (AC) and the combination on the microbiota and symptoms of healthy humans. Healthy subjects were randomized to one of 4 study groups: SB for 14 days, AC for 7 days, SB plus AC, Control (no treatment). Participants gave stool samples and completed gastro-intestinal symptom questionnaires...
January 2, 2017: Gut Microbes
https://www.readbyqxmd.com/read/27690622/-ramucirumab-a-new-anticancer-agent
#8
András Telekes, Dániel Deme
Ramucirumab is a humanized monoclonal antibody against vascular endothelial growth factor receptor-2, which inhibits the binding of vascular endothelial growth factor-A, -C and -D ligands. Furthermore it blocks the ligand stimulated activation of p44/p42 mitogen activated protein kinases, thus neutralizing the ligand induced proliferation and migration of human endothelial cells. Based on the results of the REGARD (Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma) and the RAINBOW (Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma) studies ramucirumab was approved for 2nd line treatment as monotherapy and in combination with paclitaxel for patients with local relapse and unresectable or metastatic gastric cancer (including gastro-esophegal junction adenocarcinoma)...
October 2016: Orvosi Hetilap
https://www.readbyqxmd.com/read/27571499/nintedanib-in-combination-with-docetaxel-for-second-line-treatment-of-advanced-non-small-cell-lung-cancer-genesis-sefh-drug-evaluation-report
#9
María Espinosa Bosch, Rocío Asensi Diez, Sara García Agudo, Ana Clopes Estela
Nintedanib is a triple angiokinase inhibitor that has been approved by the European Agency Medicines (EMA) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non small cell lung cancer (NSCLC) of adenocarcinoma tumour histology, after first-line chemotherapy. In LUME-Lung 1 clinical trial, the combination of nintedanib plus docetaxel vs. placebo plus docetaxel improved progression free survival (PFS) in NSCLC patients, and improved overall survival in the population of adenocarcinoma patients, particularly in those with progression within 9 months after first line treatment initiation, median 10...
June 1, 2016: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/27432490/molecular-targeted-first-line-therapy-for-advanced-gastric-cancer
#10
REVIEW
Huan Song, Jianwei Zhu, DongHao Lu
BACKGROUND: Gastric cancer is the fifth most common cancer and third leading cause of cancer-related deaths worldwide. Complete resection of the whole tumor remains the only approach to treat this malignant disease. Since gastric cancer is usually asymptomatic in its early stages, many people are diagnosed at an advanced stage when the tumor is inoperable. In addition, because other conventional treatments (radiotherapy and chemotherapy) have only modest efficacy for those with advanced/metastatic gastric cancer, the prognosis in such cases is poor...
July 19, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27363335/a-bispecific-anti-erbb2-antibody-potently-induces-erbb2-internalization-and-suppresses-erbb2-overexpressing-tumor-growth
#11
Yajun Zhang, Lingfei Wang, Xiaodan Chong, Xiaojie Yu, Yanchun Meng, Jian Dong, Chao Wang, Huajing Wang, Yang Yang, Tian Xia, Jian Zhao, Bohua Li
The anti-ErbB2 humanized antibody trastuzumab was approved for ErbB2-positive metastatic gastric and gastro-esophageal junction cancer in 2010. Despite the effectiveness of trastuzumab, its efficacy remains variable and often modest. Thus, there is an urgent need to improve ErbB2-targeting therapy. Down-regulation of surface receptors induced by monoclonal antibody (mAb) contributes to its antitumor efficacy. Previous studies have demonstrated that if two anti-ErbB2 mAbs did not compete with each other for binding to ErbB2, the combination of them can enhance ErbB2 internalization...
September 2, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/27323443/-clinical-trial-of-acupuncture-treatment-of-gastro-esophageal-reflex-disease-by-needling-dorsal-segment-of-the-governor-vessel
#12
RANDOMIZED CONTROLLED TRIAL
Lu-jiao Gao, Xing-hua Bai
OBJECTIVE: To observe the curative effect of needling stimulation of the dorsal segment (7 spots below the spinous processes from T3 to T9) of the Governor Vessel for gastro-esophageal reflux disease (GERD). METHODS: A total of 60 cases of GERD patients were randomly divided into acupuncture group and medication group (n = 30 in each group). For patients of the acupuncture group, the depression spots below the spinous processes from T3 to T9, including both acupoints [Shenzhu (GV 12), Shendao (GV 11), Lingtai (GV 10), Zhiyang (GV 9), Jinsuo (GV 8)] and non-acupoints (T4, T8) were punctured with filiform needles, once every other day for 8 weeks...
April 2016: Zhen Ci Yan Jiu, Acupuncture Research
https://www.readbyqxmd.com/read/27179107/effectiveness-of-add-on-therapy-with-domperidone-vs-alginic-acid-in-proton-pump-inhibitor-partial-response-gastro-oesophageal-reflux-disease-in-systemic-sclerosis-randomized-placebo-controlled-trial
#13
Chingching Foocharoen, Kitti Chunlertrith, Pisaln Mairiang, Ajanee Mahakkanukrauh, Siraphop Suwannaroj, Suwassa Namvijit, Orathai Wantha, Ratanavadee Nanagara
OBJECTIVES: Twice-daily dosing of proton pump inhibitor (PPI), the standard therapy for gastro-oesophageal reflux disease (GERD), is an effective therapy for GERD in SSc. The aim of this study was to compare the efficacy of omeprazole in combination with domperidone vs in combination with algycon in reducing the severity and frequency of reflux symptoms of PPI partial response (PPI-PR) GERD in SSc. METHODS: Adult SSc patients having PPI-PR GERD were randomly assigned to receive domperidone plus algycon placebo or algycon plus domperidone placebo in a 1:1 ratio plus omeprazole for 4 weeks...
February 2017: Rheumatology
https://www.readbyqxmd.com/read/27114695/ulcer-protective-activity-of-jatropha-gossypiifolia-linn-in-wistar-rats
#14
Arumugam Ramamoorthy Vijayakumar, Epison Prabu Daniel, Raju Ilavarasan, S Venkataraman, S Vijayakumar
BACKGROUND: Several synthetic drugs are useful in the treatment of peptic ulcer, but almost of these drugs are used in prolonging time, it may cause several adverse reactions. However, the herbal medicines are more potent to the treatment and minimize the side effects. OBJECTIVE: To evaluate the methanol extract of Jatropha gossypiifolia Linn. (MEJG) for gastro protective activity against Wistar rats. MATERIALS AND METHODS: Anti-ulcer potency of MEJG (100 and 200 mg/kg, b...
March 2016: Pharmacognosy Research
https://www.readbyqxmd.com/read/27114605/response-to-cetuximab-with-or-without-irinotecan-in-patients-with-refractory-metastatic-colorectal-cancer-harboring-the-kras-g13d-mutation-australasian-gastro-intestinal-trials-group-icecream-study
#15
Eva Segelov, Subotheni Thavaneswaran, Paul M Waring, Jayesh Desai, Kristy P Robledo, Val J Gebski, Elena Elez, Louise M Nott, Christos S Karapetis, Sebastian Lunke, Lorraine A Chantrill, Nick Pavlakis, Mustafa Khasraw, Craig Underhill, Fortunato Ciardiello, Michael Jefford, Harpreet Wasan, Andrew Haydon, Timothy J Price, Guy van Hazel, Kate Wilson, John Simes, Jeremy D Shapiro
PURPOSE: RAS mutations predict lack of response to epidermal growth factor receptor monoclonal antibody therapy in patients with metastatic colorectal cancer (mCRC), but preclinical studies and retrospective clinical data suggest that patients with tumors harboring the exon 2 KRAS G13D mutation may benefit from cetuximab. We aimed to assess cetuximab monotherapy and cetuximab plus irinotecan in patients with molecularly selected (G13D mutation) chemotherapy-refractory mCRC in a randomized phase II trial of this rare molecular subtype...
July 1, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27111831/non-surgical-interventions-for-late-rectal-problems-proctopathy-of-radiotherapy-in-people-who-have-received-radiotherapy-to-the-pelvis
#16
REVIEW
Fleur T van de Wetering, Leen Verleye, H Jervoise N Andreyev, Jane Maher, Joan Vlayen, Bradley R Pieters, Geertjan van Tienhoven, Rob J P M Scholten
BACKGROUND: This is an update of a Cochrane review first published in 2002, and previously updated in 2007. Late radiation rectal problems (proctopathy) include bleeding, pain, faecal urgency, and incontinence and may develop after pelvic radiotherapy treatment for cancer. OBJECTIVES: To assess the effectiveness and safety of non-surgical interventions for managing late radiation proctopathy. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 11, 2015); MEDLINE (Ovid); EMBASE (Ovid); CANCERCD; Science Citation Index; and CINAHL from inception to November 2015...
April 25, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27014758/recent-strategies-for-treating-stage-iv-gastric-cancer-roles-of-palliative-gastrectomy-chemotherapy-and-radiotherapy
#17
REVIEW
Kunihiko Izuishi, Hirohito Mori
Recently, many strategies have been reported for the effective treatment of gastric cancer. However, the strategy for treating stage IV gastric cancer remains controversial. Conducting a prospective phase III study in stage IV cancer patients is difficult because of heterogeneous performance status, age, and degree of cancer metastasis or extension. Due to poor prognosis, the variance in physical status, and severe symptoms, it is important to determine the optimal strategy for treating each individual stage IV patient...
March 2016: Journal of Gastrointestinal and Liver Diseases: JGLD
https://www.readbyqxmd.com/read/26969261/evaluating-and-optimizing-oral-formulations-of-live-bacterial-vaccines-using-a-gastro-small-intestine-model
#18
João M S de Barros, Adele Costabile, Dimitrios Charalampopoulos, Vitaliy V Khutoryanskiy, Alexander D Edwards
Gastrointestinal (GI) models that mimic physiological conditions in vitro are important tools for developing and optimizing biopharmaceutical formulations. Oral administration of live attenuated bacterial vaccines (LBV) can safely and effectively promote mucosal immunity but new formulations are required that provide controlled release of optimal numbers of viable bacterial cells, which must survive gastrointestinal transit overcoming various antimicrobial barriers. Here, we use a gastro-small intestine gut model of human GI conditions to study the survival and release kinetics of two oral LBV formulations: the licensed typhoid fever vaccine Vivotif comprising enteric coated capsules; and an experimental formulation of the model vaccine Salmonella Typhimurium SL3261 dried directly onto cast enteric polymer films and laminated to form a polymer film laminate (PFL)...
May 2016: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/26845174/chemoradiotherapy-with-folfox-plus-cetuximab-in-locally-advanced-oesophageal-cancer-the-gercor-phase-ii-trial-erafox
#19
MULTICENTER STUDY
Gérard Lledo, Florence Huguet, Benoist Chibaudel, Frédéric Di Fiore, Laurent Mineur, Marie-Pierre Galais, Pascal Artru, Valérie Blondin, Olivier Dupuis, Menouar Samir Abdiche, Nicolas Jovenin, Astrid Pozet, Franck Bonnetain, Mohamed Attia, Laetitia Dahan, Aimery de Gramont
BACKGROUND: To determine efficacy and toxicity of radiation therapy combined with oxaliplatin, 5-fluorouracil, and folinic acid (FOLFOX) and cetuximab in patients with locally advanced oesophageal cancer. PATIENTS AND METHODS: Patients with stage III oesophageal or gastro-oesophageal junction cancer were enrolled in a Simon's two-stage phase II study. Patients received FOLFOX and weekly cetuximab on week 1-10 with concurrent radiotherapy (50.4 Gy in 30 fractions) on week 5-10...
March 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/26633306/leukoreduction-for-the-prevention-of-adverse-reactions-from-allogeneic-blood-transfusion
#20
REVIEW
Daniel Simancas-Racines, Dimelza Osorio, Arturo J Martí-Carvajal, Ingrid Arevalo-Rodriguez
BACKGROUND: A blood transfusion is an acute intervention, implemented to solve life and health-threatening conditions on a short-term basis. However, blood transfusions have adverse events, some of them potentially related to immune modulation or to a direct transmission of infectious agents (e.g. cytomegalovirus). Leukoreduction is a process in which the white blood cells are intentionally reduced in packed red blood cells (PRBCs) in order to reduce the risk of adverse reactions. The potential benefits of leukoreduced PRBCs in all types of transfused patients for decreasing infectious and non-infectious complications remain unclear...
December 3, 2015: Cochrane Database of Systematic Reviews
keyword
keyword
79672
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"